GlassScriptPhysician profile
Tosha Jo Johnson
NPI 1639214216
$25,751.87
in general payments reported to CMS, 2019-2025
23 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,905 · 2022: $12K · 2023: $4,161 · 2024: $225 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,800 · Food and Beverage: $1,747 · Travel and Lodging: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,800.00 |
| Food and Beverage | $1,746.54 |
| Travel and Lodging | $1,290.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $18,069.66 | 2021-2023 | Uptravi, Opsumit |
| Abbott Laboratories | $2,448.53 | 2021-2023 | Cardiomems |
| Medtronic, INC. | $1,451.04 | 2025 | Micra, Linq II, Attain Command + Surevalve |
| E.R. Squibb & Sons, L.L.C. | $1,105.14 | 2021-2023 | Camzyos, Eliquis |
| Amgen INC. | $459.43 | 2021-2023 | Repatha |
| Pfizer INC. | $327.04 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $264.80 | 2021-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $263.78 | 2021-2022 | |
| Abiomed | $206.12 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $176.12 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $166.43 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $159.07 | 2022-2023 | Lifevest |
| Irhythm Technologies, INC. | $151.64 | 2021-2023 | Zio Xt Patch |
| Merck Sharp & Dohme LLC | $90.58 | 2022 | |
| Abbvie INC. | $87.25 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $83.27 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $74.90 | 2021-2022 | |
| Edwards Lifesciences Corporation | $59.31 | 2022-2024 | |
| United Therapeutics Corporation | $43.61 | 2021 | |
| Esperion Therapeutics, INC. | $17.57 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $17.21 | 2023 | Arcalyst |
| Sandoz INC. | $17.19 | 2023 | Treprostinil |
| Preventice Services, LLC | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tosha Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.